What is Gossamer Bio's operating income?

Gossamer Bio's total operating income in 2025 was -$170.73 million, based on the following breakdown: Total Gross Profit: $48.47 million Total Operating Expenses: $219.20 million

Gossamer Bio (GOSS) Financials

$0.14 -0.03 (-17.11%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$0.14 +0.00 (+2.84%)

As of 06:00 AM Eastern

Compare

Annual Income Statements for Gossamer Bio

This table shows Gossamer Bio's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-6.77	-147	-180	-243	-234	-229	-180	-57	-170
Consolidated Net Income / (Loss)	-6.77	-147	-180	-243	-234	-229	-180	-57	-170
Net Income / (Loss) Continuing Operations	-6.77	-147	-180	-243	-234	-229	-180	-57	-170
Total Pre-Tax Income	-6.65	-147	-180	-243	-234	-229	-180	-56	-170
Total Operating Income	-6.65	-149	-186	-234	-216	-219	-184	-60	-171
Total Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00	0.00	115	48
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	115	48
Operating Revenue	-	-	-	-	-	0.00	-	115	48
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	6.65	149	186	234	216	219	184	175	219
Selling, General & Admin Expense	0.26	44	39	50	46	48	38	36	38
Research & Development Expense	6.39	105	147	184	170	171	145	138	182
Total Other Income / (Expense), net	0.00	2.02	5.83	-9.40	-18	-11	3.94	4.28	0.27
Interest Expense	-	0.01	1.94	13	19	14	14	12	11
Interest & Investment Income	-	1.72	5.56	3.44	0.76	1.58	2.00	1.78	1.97
Other Income / (Expense), net	-	0.32	2.21	-0.17	0.80	1.51	15	14	9.29
Income Tax Expense	-	-	-	-	-	0.00	0.00	0.89	-0.09
Basic Earnings per Share	($0.74)	($22.59)	($3.29)	($3.55)	($3.13)	($2.71)	($1.18)	($0.25)	($0.75)
Weighted Average Basic Shares Outstanding	9.16M	6.50M	54.74M	68.51M	74.84M	84.57M	152.62M	226.23M	228.52M
Diluted Earnings per Share	($0.74)	($22.59)	($3.29)	($3.55)	($3.13)	($2.71)	($1.18)	($0.25)	($0.75)
Weighted Average Diluted Shares Outstanding	9.16M	6.50M	54.74M	68.51M	74.84M	84.57M	152.62M	226.23M	228.52M
Weighted Average Basic & Diluted Shares Outstanding	9.16M	6.50M	54.74M	68.51M	76.48M	94.98M	225.58M	227.22M	234.70M

This table shows Gossamer Bio's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-40	-48	-42	49	-31	-31	-37	-38	-48	-47	-47
Consolidated Net Income / (Loss)	-40	-48	-42	49	-31	-33	-37	-38	-48	-47	-47
Net Income / (Loss) Continuing Operations	-40	-48	-42	49	-31	-33	-37	-38	-48	-47	-47
Total Pre-Tax Income	-40	-48	-42	54	-32	-35	-37	-38	-48	-47	-47
Total Operating Income	-40	-49	-42	52	-34	-36	-37	-39	-49	-46	-45
Total Gross Profit	0.00	-	0.00	96	9.48	9.38	9.89	11	13	14	17
Total Revenue	0.00	-	0.00	96	9.48	9.38	9.89	11	13	14	17
Operating Revenue	0.00	-	0.00	96	9.48	-	9.89	11	13	14	17
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	40	49	42	44	43	46	47	50	62	60	62
Selling, General & Admin Expense	9.29	9.06	9.57	8.67	8.50	9.40	8.66	8.68	9.39	11	19
Research & Development Expense	31	40	32	35	35	36	38	42	53	49	43
Total Other Income / (Expense), net	0.48	0.88	0.03	1.58	1.98	0.69	0.17	0.49	0.89	-1.29	-1.80
Interest Expense	3.34	3.24	3.13	2.92	2.73	2.74	2.75	2.74	2.75	2.75	2.76
Interest & Investment Income	0.41	0.31	0.34	1.75	0.43	-0.74	0.29	0.54	0.69	0.45	0.35
Other Income / (Expense), net	3.42	3.81	2.82	2.75	4.29	4.17	2.62	2.69	2.95	1.02	0.60
Basic Earnings per Share	($0.21)	-	($0.19)	$0.22	($0.14)	($0.14)	($0.16)	($0.17)	($0.21)	($0.21)	($0.20)
Weighted Average Basic Shares Outstanding	192.88M	152.62M	225.74M	226.22M	226.35M	226.23M	226.82M	227.28M	227.98M	228.52M	234.14M
Diluted Earnings per Share	($0.21)	-	($0.19)	$0.22	($0.14)	($0.14)	($0.16)	($0.17)	($0.21)	($0.21)	($0.20)
Weighted Average Diluted Shares Outstanding	192.88M	152.62M	225.74M	238.54M	226.35M	226.23M	226.82M	227.28M	227.98M	228.52M	234.14M
Weighted Average Basic & Diluted Shares Outstanding	225.41M	225.58M	226.22M	226.23M	226.60M	227.22M	227.30M	227.38M	231.46M	234.70M	234.70M

This table details how cash moves in and out of Gossamer Bio's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	105	30	352	-303	-71	-80	14	-8.34
Net Cash From Operating Activities	-51	-145	-176	-189	-187	-159	-3.47	-171
Net Cash From Continuing Operating Activities	-51	-145	-176	-189	-187	-159	-3.47	-171
Net Income / (Loss) Continuing Operations	-147	-180	-243	-234	-229	-180	-57	-170
Consolidated Net Income / (Loss)	-147	-180	-243	-234	-229	-180	-57	-170
Depreciation Expense	0.30	0.92	1.41	1.74	1.83	1.61	0.83	0.02
Amortization Expense	0.00	0.05	6.81	10	2.36	-5.35	-8.66	-5.32
Non-Cash Adjustments To Reconcile Net Income	91	33	53	38	42	31	24	23
Changes in Operating Assets and Liabilities, net	4.50	1.52	5.73	-5.00	-3.88	-6.99	37	-19
Net Cash From Investing Activities	-145	-147	215	-117	-1.04	-111	29	156
Net Cash From Continuing Investing Activities	-145	-147	215	-117	-1.04	-111	29	156
Purchase of Property, Plant & Equipment	-3.49	-2.97	-1.50	-1.55	-0.41	0.00	0.00	-0.08
Purchase of Investments	-124	-499	-109	-152	-238	-442	-495	-227
Sale and/or Maturity of Investments	0.00	359	349	36	238	331	524	384
Net Cash From Financing Activities	301	322	313	3.33	117	190	-11	6.43
Net Cash From Continuing Financing Activities	301	322	313	3.33	117	190	-11	6.43
Repayment of Debt	-0.04	-	0.00	0.00	-5.81	-12	-13	0.00
Issuance of Common Equity	0.00	291	118	1.32	121	202	1.09	0.84
Other Financing Activities, net	-2.14	2.05	0.53	2.01	1.74	0.00	0.00	5.59
Effect of Exchange Rate Changes	-	0.07	0.01	-0.17	-0.52	0.11	-0.10	0.14
Cash Interest Paid	0.12	1.48	7.87	13	13	12	11	10

This table details how cash moves in and out of Gossamer Bio's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	46	-51	6.75	48	-58	18	-17	-2.71	-17	29	3.30
Net Cash From Operating Activities	-34	-33	-52	116	-32	-35	-40	-47	-36	-48	-39
Net Cash From Continuing Operating Activities	-34	-33	-52	116	-32	-35	-40	-47	-36	-48	-39
Net Income / (Loss) Continuing Operations	-40	-48	-42	49	-31	-33	-37	-38	-48	-47	-47
Consolidated Net Income / (Loss)	-40	-48	-42	49	-31	-33	-37	-38	-48	-47	-47
Depreciation Expense	0.39	0.29	0.26	0.25	0.22	0.11	0.01	0.01	0.01	0.01	0.01
Amortization Expense	-1.81	-2.56	-2.03	-1.93	-2.54	-2.16	-2.09	-1.49	-1.12	-0.61	-0.18
Non-Cash Adjustments To Reconcile Net Income	6.79	12	7.28	6.93	4.56	61	6.71	3.43	12	0.49	2.04
Changes in Operating Assets and Liabilities, net	0.15	5.17	-16	62	-3.47	-62	-7.71	-11	0.89	-0.96	6.08
Net Cash From Investing Activities	-118	-14	62	-59	-27	53	22	44	17	73	42
Net Cash From Continuing Investing Activities	-118	-14	62	-59	-27	53	22	44	17	73	42
Purchase of Property, Plant & Equipment	-	-	0.00	-	-	-	-0.03	-0.05	-	-	0.00
Purchase of Investments	-188	-120	-86	-194	-131	-84	-101	-76	-30	-21	-25
Sale and/or Maturity of Investments	70	106	148	135	105	137	123	120	47	94	67
Net Cash From Financing Activities	198	-2.90	-2.56	-9.21	0.28	-	0.50	0.09	1.87	3.96	0.51
Net Cash From Continuing Financing Activities	198	-2.90	-2.56	-9.21	0.28	-	0.50	0.09	1.87	3.96	0.51
Issuance of Common Equity	201	-	0.35	-	0.28	0.46	0.37	-	0.47	-0.00	0.29
Other Financing Activities, net	-	-	0.00	0.46	-	-0.46	0.13	0.09	1.40	3.96	0.22
Effect of Exchange Rate Changes	-0.14	0.19	-0.06	-0.01	0.09	-0.13	0.11	0.13	-0.10	0.00	-0.10
Cash Interest Paid	0.55	5.46	0.37	5.19	-	5.00	0.00	5.00	-	5.00	0.00

This table presents Gossamer Bio's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	239	427	539	344	272	312	315	172
Total Current Assets	232	409	522	332	262	307	310	168
Cash & Equivalents	105	135	486	183	112	32	46	38
Short-Term Investments	123	267	27	142	144	264	248	99
Accounts Receivable	-	-	-	-	-	0.00	5.34	12
Prepaid Expenses	3.10	7.49	9.13	6.50	6.20	10	10	18
Plant, Property, & Equipment, net	3.19	5.43	5.53	5.32	3.98	1.65	0.01	0.06
Total Noncurrent Assets	4.27	12	12	6.56	6.59	3.75	5.39	4.54
Other Noncurrent Operating Assets	4.27	12	12	6.56	6.59	3.75	5.39	4.54
Total Liabilities & Shareholders' Equity	239	427	539	344	272	312	315	172
Total Liabilities	21	74	219	222	260	249	286	295
Total Current Liabilities	20	37	39	40	49	52	45	63
Accounts Payable	2.18	0.96	7.51	3.24	1.46	5.53	2.32	5.96
Accrued Expenses	18	36	31	37	36	34	26	37
Current Deferred Revenue	-	-	-	-	-	0.00	17	20
Total Noncurrent Liabilities	0.72	37	180	182	211	198	241	232
Long-Term Debt	0.00	28	172	179	208	197	198	199
Noncurrent Deferred Revenue	-	-	-	-	-	0.00	39	30
Other Noncurrent Operating Liabilities	0.72	8.74	7.71	3.22	3.45	0.14	4.40	3.46
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-120	352	321	121	12	63	29	-123
Total Preferred & Common Equity	-120	352	321	121	12	63	29	-123
Total Common Equity	-120	352	321	121	12	63	29	-123
Common Stock	34	686	898	933	1,045	1,275	1,297	1,321
Retained Earnings	-154	-334	-578	-812	-1,032	-1,212	-1,269	-1,439
Accumulated Other Comprehensive Income / (Loss)	-0.06	0.26	0.60	0.05	-0.57	-0.35	1.19	-5.15

This table presents Gossamer Bio's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	348	259	373	351	281	241	209	129
Total Current Assets	341	255	371	344	275	236	204	125
Cash & Equivalents	83	39	87	28	29	26	8.93	41
Short-Term Investments	246	206	268	299	229	187	171	58
Accounts Receivable	-	-	3.63	6.59	6.58	7.58	9.24	9.25
Prepaid Expenses	13	11	13	11	11	15	15	16
Plant, Property, & Equipment, net	1.94	1.07	0.82	0.30	0.03	0.08	0.07	0.06
Total Noncurrent Assets	4.49	3.02	1.72	6.31	5.09	4.95	4.76	4.30
Other Noncurrent Operating Assets	4.49	3.02	1.72	6.31	5.09	4.95	4.76	4.30
Total Liabilities & Shareholders' Equity	348	259	373	351	281	241	209	129
Total Liabilities	243	233	292	297	287	287	291	290
Total Current Liabilities	42	36	45	51	48	54	62	57
Accounts Payable	1.25	2.66	1.00	3.06	3.39	1.88	1.12	11
Accrued Expenses	29	24	27	28	27	28	37	37
Current Deferred Revenue	-	-	17	20	18	23	24	8.74
Total Noncurrent Liabilities	201	197	247	246	239	233	229	234
Long-Term Debt	200	197	197	197	198	198	198	199
Noncurrent Deferred Revenue	-	-	50	44	37	31	27	32
Other Noncurrent Operating Liabilities	0.99	0.00	0.00	4.59	4.17	3.93	3.70	3.21
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	105	27	82	54	-6.25	-46	-82	-161
Total Preferred & Common Equity	105	27	82	54	-6.25	-46	-82	-161
Total Common Equity	105	27	82	54	-6.25	-46	-82	-161
Common Stock	1,269	1,281	1,287	1,292	1,300	1,302	1,314	1,328
Retained Earnings	-1,164	-1,254	-1,205	-1,236	-1,305	-1,343	-1,392	-1,486
Accumulated Other Comprehensive Income / (Loss)	-0.62	-0.63	-0.52	-2.23	-0.82	-5.09	-5.11	-4.02

This table displays calculated financial ratios and metrics derived from Gossamer Bio's official financial filings.

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	0.00	0.00	66,038,122.00	75,927,877.00	76,463,531.00	94,476,801.00	225,409,314.00	-	231,456,247.00
DEI Adjusted Shares Outstanding	0.00	0.00	66,038,122.00	75,927,877.00	76,463,531.00	94,476,801.00	225,409,314.00	-	231,456,247.00
DEI Earnings Per Adjusted Shares Outstanding	0.00	0.00	-2.73	-3.21	-3.06	-2.43	-0.80	-	-0.74
Growth Metrics	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-57.74%
EBITDA Growth	0.00%	-2,130.27%	-23.31%	-23.47%	10.10%	-4.83%	19.19%	68.77%	-210.36%
EBIT Growth	0.00%	-2,134.74%	-23.71%	-27.29%	8.03%	-0.82%	22.47%	72.73%	-251.74%
NOPAT Growth	0.00%	-2,139.49%	-24.93%	-25.69%	7.62%	-1.14%	15.94%	67.39%	-184.93%
Net Income Growth	0.00%	-2,070.57%	-22.68%	-34.97%	3.84%	1.98%	21.61%	68.56%	-201.39%
EPS Growth	0.00%	-2,952.70%	85.44%	-7.90%	11.83%	13.42%	56.46%	78.81%	-200.00%
Operating Cash Flow Growth	0.00%	0.00%	-183.74%	-21.77%	-7.10%	0.98%	14.90%	97.82%	-4,838.47%
Free Cash Flow Firm Growth	0.00%	0.00%	-27.99%	-37.14%	10.84%	-4.58%	16.39%	100.72%	-13,751.80%
Invested Capital Growth	0.00%	0.00%	-97.77%	3.65%	-22.76%	1.66%	-1.43%	-173.98%	9.36%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	8.91%	10.03%
EBITDA Q/Q Growth	0.00%	0.00%	46.16%	-1.12%	6.19%	-4.26%	2.91%	20.06%	-7.49%
EBIT Q/Q Growth	0.00%	0.00%	45.95%	-1.95%	5.72%	-2.72%	4.37%	22.42%	-8.81%
NOPAT Q/Q Growth	0.00%	0.00%	45.30%	-1.87%	3.75%	-1.25%	2.82%	17.71%	-6.16%
Net Income Q/Q Growth	0.00%	0.00%	-9.67%	-4.24%	3.43%	0.23%	4.06%	21.10%	-9.10%
EPS Q/Q Growth	0.00%	0.00%	54.31%	-0.85%	3.99%	6.55%	32.18%	-127.27%	-10.29%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	-15.21%	4.03%	-2.04%	-4.02%	8.25%	-145.78%	-8.10%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	11.90%	2.67%	-15.94%	18.50%	-92.31%	-1.57%
Invested Capital Q/Q Growth	0.00%	0.00%	45.69%	-61.58%	-30.66%	35.57%	-94.64%	10.73%	4.85%
Profitability Metrics	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	100.00%	100.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-46.84%	-343.98%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-52.24%	-352.23%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-40.01%	-333.06%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-49.28%	-351.49%
Tax Burden Percent	101.77%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	101.61%	99.95%
Interest Burden Percent	100.00%	98.85%	98.03%	103.94%	108.67%	105.66%	106.84%	121.22%	105.59%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	0.00%	122.40%	-155.16%	-72.30%	-105.85%	-343.53%	-480.50%	-122.54%	365.33%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-14.64%	-66.23%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-18.03%	-69.89%
Return on Common Equity (ROCE)	0.00%	122.40%	-155.16%	-72.30%	-105.85%	-343.53%	-480.50%	-122.54%	365.33%
Return on Equity Simple (ROE_SIMPLE)	0.00%	122.40%	-51.15%	-75.89%	-192.65%	-1,899.30%	0.00%	-191.67%	0.00%
Net Operating Profit after Tax (NOPAT)	-4.66	-104	-130	-164	-151	-153	-129	-42	-120
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-36.57%	-246.56%
Net Nonoperating Expense Percent (NNEP)	0.00%	77.94%	-37.91%	-22.29%	-33.97%	-83.67%	-82.71%	-15.82%	-287.19%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-66.13%	-47.33%	-18.48%	-157.77%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	31.50%	77.64%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	120.74%	374.59%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	152.24%	452.23%
Earnings before Interest and Taxes (EBIT)	-6.65	-149	-184	-234	-215	-217	-168	-46	-161
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-6.65	-148	-183	-226	-203	-213	-172	-54	-167
Valuation Ratios	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	2.93	2.29	7.12	16.98	3.28	6.95	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	2.93	2.29	7.12	16.98	3.28	6.95	0.00
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.79	14.80
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.94	16.07
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	117.17	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.08	0.54	1.47	18.16	3.33	6.70	-1.62
Long-Term Debt to Equity	0.00	0.00	0.08	0.54	1.47	17.20	3.14	6.70	-1.62
Financial Leverage	0.00	-0.91	-1.14	-1.06	-1.10	-1.37	-1.65	-2.00	0.38
Leverage Ratio	0.00	-1.99	2.87	1.44	2.00	4.61	7.81	6.80	-5.23
Compound Leverage Factor	0.00	-1.97	2.81	1.49	2.17	4.88	8.34	8.24	-5.52
Debt to Total Capital	0.00%	0.00%	7.47%	34.96%	59.59%	94.78%	76.91%	87.01%	262.06%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	5.02%	4.27%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	7.47%	34.96%	59.59%	89.76%	72.63%	87.01%	262.06%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	100.00%	92.53%	65.04%	40.41%	5.22%	23.09%	12.99%	-162.06%
Debt to EBITDA	0.00	0.00	-0.16	-0.76	-0.88	-1.03	-1.21	-3.68	-1.19
Net Debt to EBITDA	0.00	0.00	2.04	1.51	0.72	0.17	0.51	1.81	-0.37
Long-Term Debt to EBITDA	0.00	0.00	-0.16	-0.76	-0.88	-0.98	-1.15	-3.68	-1.19
Debt to NOPAT	0.00	0.00	-0.22	-1.05	-1.18	-1.43	-1.62	-4.71	-1.66
Net Debt to NOPAT	0.00	0.00	2.87	2.08	0.97	0.24	0.68	2.31	-0.52
Long-Term Debt to NOPAT	0.00	0.00	-0.22	-1.05	-1.18	-1.36	-1.53	-4.71	-1.66
Altman Z-Score	0.00	5.95	6.88	0.16	-2.02	-6.52	-5.74	-4.31	-12.32
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-
Current Ratio	0.00	11.37	11.09	13.51	8.32	5.32	5.94	6.88	2.64
Quick Ratio	0.00	11.21	10.88	13.26	8.16	5.19	5.74	6.66	2.35
Cash Flow Metrics	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-94	-120	-165	-147	-153	-128	0.92	-126
Operating Cash Flow to CapEx	0.00%	-1,462.58%	-4,883.14%	-11,733.87%	-12,217.98%	-45,617.56%	0.00%	0.00%	-216,792.41%
Free Cash Flow to Firm to Interest Expense	0.00	-7,811.26	-61.91	-12.99	-7.55	-11.05	-9.49	0.08	-11.45
Operating Cash Flow to Interest Expense	0.00	-4,253.67	-74.73	-13.92	-9.72	-13.47	-11.78	-0.30	-15.59
Operating Cash Flow Less CapEx to Interest Expense	0.00	-4,544.50	-76.26	-14.04	-9.80	-13.50	-11.78	-0.30	-15.59
Efficiency Ratios	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.37	0.20
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.52
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	138.36	1,310.03
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	66.13
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	66.13
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-
Invested Capital	0.00	-11	-21	-20	-25	-24	-25	-68	-61
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-2.49	-0.75
Increase / (Decrease) in Invested Capital	0.00	-11	-10	0.76	-4.58	0.41	-0.35	-43	6.32
Enterprise Value (EV)	0.00	47	659	393	719	169	118	108	779
Market Capitalization	276	276	1,032	734	865	205	206	205	718
Book Value per Share	$0.00	($18.46)	$5.34	$4.22	$1.59	$0.13	$0.28	$0.13	($0.53)
Tangible Book Value per Share	$0.00	($18.46)	$5.34	$4.22	$1.59	$0.13	$0.28	$0.13	($0.53)
Total Capital	0.00	-120	381	493	301	231	272	227	76
Total Debt	0.00	0.00	28	172	179	219	209	198	199
Total Long-Term Debt	0.00	0.00	28	172	179	208	197	198	199
Net Debt	0.00	-229	-373	-341	-146	-36	-87	-97	62
Capital Expenditures (CapEx)	0.00	3.49	2.97	1.50	1.55	0.41	0.00	0.00	0.08
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	-17	-29	-30	-33	-31	-30	-30	-33
Debt-free Net Working Capital (DFNWC)	0.00	212	372	484	292	224	267	265	104
Net Working Capital (NWC)	0.00	212	372	484	292	213	255	265	104
Net Nonoperating Expense (NNE)	2.11	43	50	80	83	76	51	15	51
Net Nonoperating Obligations (NNO)	0.00	110	-373	-341	-146	-36	-87	-97	62
Total Depreciation and Amortization (D&A)	0.00	0.30	0.96	8.22	12	4.19	-3.74	-7.83	-5.29
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-25.84%	-67.51%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	230.93%	214.99%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	230.93%	214.99%
Earnings Adjustments	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	($3.29)	($3.55)	($3.13)	($2.71)	($1.18)	($0.25)	($0.75)
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	66.34M	75.53M	74.84M	84.57M	152.62M	226.23M	228.52M
Adjusted Diluted Earnings per Share	$0.00	$0.00	($3.29)	($3.55)	($3.13)	($2.71)	($1.18)	($0.25)	($0.75)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	66.34M	75.53M	74.84M	84.57M	152.62M	226.23M	228.52M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	($3.29)	($3.55)	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	54.74M	68.51M	76.48M	94.98M	225.58M	227.22M	234.70M
Normalized Net Operating Profit after Tax (NOPAT)	-4.66	-104	-130	-164	-151	-153	-129	-42	-120
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-36.57%	-246.56%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-48.50%	-351.67%
Debt Service Ratios	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	-12,389.75	-94.91	-18.49	-11.08	-15.64	-12.46	-3.99	-14.69
NOPAT to Interest Expense	0.00	-8,691.26	-67.23	-12.93	-7.78	-11.02	-9.52	-3.64	-10.88
EBIT Less CapEx to Interest Expense	0.00	-12,680.58	-96.44	-18.60	-11.16	-15.67	-12.46	-3.99	-14.70
NOPAT Less CapEx to Interest Expense	0.00	-8,982.09	-68.76	-13.05	-7.86	-11.05	-9.52	-3.64	-10.88
Payout Ratios	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Gossamer Bio's official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	225,322,142.00	225,409,314.00	225,582,250.00	226,218,652.00	226,227,259.00	-	227,221,261.00	227,302,140.00	227,380,609.00	231,456,247.00	234,696,281.00
DEI Adjusted Shares Outstanding	225,322,142.00	225,409,314.00	225,582,250.00	226,218,652.00	226,227,259.00	-	227,221,261.00	227,302,140.00	227,380,609.00	231,456,247.00	234,696,281.00
DEI Earnings Per Adjusted Shares Outstanding	-0.18	-0.21	-0.19	0.22	-0.14	-	-0.16	-0.17	-0.21	-0.20	-0.20
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-88.01%	40.23%	47.13%	71.45%
EBITDA Growth	30.46%	9.81%	11.62%	233.63%	16.98%	28.38%	11.34%	-170.66%	-47.94%	-34.16%	-22.51%
EBIT Growth	34.22%	14.52%	15.37%	237.91%	20.07%	29.33%	12.66%	-165.78%	-55.78%	-40.88%	-29.48%
NOPAT Growth	27.72%	9.81%	12.48%	247.43%	16.23%	26.31%	12.27%	-156.79%	-44.80%	-27.43%	-21.89%
Net Income Growth	32.60%	13.66%	14.72%	215.85%	23.01%	31.40%	12.62%	-177.74%	-56.55%	-43.02%	-27.37%
EPS Growth	67.69%	0.00%	63.46%	148.89%	33.33%	0.00%	15.79%	-177.27%	-50.00%	-50.00%	-25.00%
Operating Cash Flow Growth	6.77%	29.97%	1.30%	404.17%	7.13%	-6.15%	24.05%	-140.45%	-12.91%	-36.17%	2.52%
Free Cash Flow Firm Growth	-161.46%	11.67%	15.09%	338.47%	173.45%	151.74%	192.83%	-137.21%	-216.53%	-319.32%	-222.12%
Invested Capital Growth	66.43%	-1.43%	16.89%	-607.24%	-497.35%	-173.98%	-489.67%	19.62%	14.96%	9.36%	6.75%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	-90.11%	-1.07%	5.44%	16.18%	15.71%	3.80%	22.87%
EBITDA Q/Q Growth	3.24%	-23.37%	13.85%	229.93%	-160.12%	-6.42%	-6.65%	-3.55%	-25.88%	3.49%	2.61%
EBIT Q/Q Growth	6.77%	-21.98%	13.44%	240.09%	-154.04%	-7.85%	-6.98%	-5.51%	-27.97%	2.47%	1.69%
NOPAT Q/Q Growth	12.55%	-21.08%	14.42%	262.68%	-149.69%	-6.51%	-1.89%	-5.31%	-26.70%	6.26%	2.55%
Net Income Q/Q Growth	5.85%	-20.35%	12.92%	217.42%	-162.57%	-7.23%	-10.93%	-4.46%	-25.99%	2.04%	1.22%
EPS Q/Q Growth	53.33%	0.00%	0.00%	215.79%	-163.64%	0.00%	-14.29%	-6.25%	-23.53%	0.00%	4.76%
Operating Cash Flow Q/Q Growth	9.82%	3.10%	-56.48%	322.45%	-127.53%	-10.76%	-11.96%	-18.47%	23.15%	-33.59%	19.86%
Free Cash Flow Firm Q/Q Growth	-12.71%	36.37%	6.80%	456.78%	-65.29%	-55.18%	67.22%	-243.00%	-8.72%	15.64%	6.89%
Invested Capital Q/Q Growth	-17.94%	-94.64%	54.28%	-573.90%	0.39%	10.73%	1.60%	8.14%	-5.38%	4.85%	-1.23%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	0.00%	0.00%	0.00%	55.46%	-337.10%	-362.60%	-366.77%	-326.90%	-355.63%	-330.65%	-262.08%
Operating Margin	0.00%	0.00%	0.00%	54.35%	-357.80%	-385.20%	-372.23%	-337.41%	-369.44%	-333.64%	-264.62%
EBIT Margin	0.00%	0.00%	0.00%	57.21%	-312.56%	-340.73%	-345.70%	-313.96%	-347.22%	-326.27%	-261.06%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	51.37%	-324.93%	-352.16%	-370.49%	-333.13%	-362.73%	-342.33%	-275.22%
Tax Burden Percent	100.00%	100.00%	100.00%	91.74%	96.46%	93.20%	100.00%	100.00%	100.00%	99.81%	100.00%
Interest Burden Percent	107.93%	106.48%	107.11%	97.87%	107.78%	110.90%	107.17%	106.10%	104.46%	105.12%	105.42%
Effective Tax Rate	0.00%	0.00%	0.00%	8.26%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-232.88%	-480.50%	19,905.42%	-863.39%	-90.26%	-122.54%	-500.57%	-783.37%	1,107.64%	365.33%	215.10%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	19.75%	-94.22%	-124.62%	-159.54%	-41.12%	-54.66%	-64.88%	-70.81%
Return on Assets (ROA)	0.00%	0.00%	0.00%	17.74%	-97.94%	-128.80%	-170.98%	-43.63%	-57.10%	-68.07%	-74.65%
Return on Common Equity (ROCE)	-232.88%	-480.50%	19,905.42%	-863.39%	-90.26%	-122.54%	-500.57%	-783.37%	1,107.64%	365.33%	215.10%
Return on Equity Simple (ROE_SIMPLE)	-179.16%	0.00%	-645.83%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-28	-34	-29	48	-24	-25	-26	-27	-34	-32	-31
NOPAT Margin	0.00%	0.00%	0.00%	49.86%	-250.46%	-269.64%	-260.56%	-236.19%	-258.61%	-233.55%	-185.23%
Net Nonoperating Expense Percent (NNEP)	-11.04%	-22.35%	-108.80%	2.75%	-5.72%	-8.39%	-22.15%	-12.92%	-24.78%	-84.76%	77.49%
Return On Investment Capital (ROIC_SIMPLE)	-	-12.63%	-12.60%	17.15%	-9.44%	-11.14%	-13.45%	-17.86%	-29.66%	-42.55%	-84.24%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	9.05%	89.68%	100.17%	87.55%	75.54%	70.63%	79.02%	110.56%
R&D to Revenue	0.00%	0.00%	0.00%	36.61%	368.11%	385.03%	384.68%	361.87%	398.81%	354.62%	254.05%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	45.65%	457.80%	485.20%	472.23%	437.41%	469.44%	433.64%	364.62%
Earnings before Interest and Taxes (EBIT)	-37	-45	-39	55	-30	-32	-34	-36	-46	-45	-44
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-38	-47	-41	53	-32	-34	-36	-38	-47	-46	-44
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.79	3.28	9.96	2.50	4.12	6.95	0.00	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	1.79	3.28	9.96	2.50	4.12	6.95	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.00	0.00	0.00	2.13	2.12	1.79	2.01	6.95	13.58	14.80	1.39
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.48	0.89	0.94	1.52	6.58	13.98	16.07	3.18
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	20.83	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	4.83	7.79	117.17	11.28	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	2.02	3.33	7.72	2.42	3.64	6.70	-31.64	-4.29	-2.41	-1.62	-1.23
Long-Term Debt to Equity	1.91	3.14	7.37	2.42	3.64	6.70	-31.64	-4.29	-2.41	-1.62	-1.23
Financial Leverage	-1.31	-1.65	13.31	-5.63	-1.56	-2.00	-4.79	-4.87	3.96	0.38	-0.23
Leverage Ratio	4.17	7.81	-276.39	29.64	4.40	6.80	26.38	17.34	-19.85	-5.23	-2.44
Compound Leverage Factor	4.50	8.31	-296.06	29.01	4.74	7.54	28.27	18.40	-20.74	-5.49	-2.57
Debt to Total Capital	66.92%	76.91%	88.54%	70.73%	78.47%	87.01%	103.26%	130.35%	171.02%	262.06%	533.16%
Short-Term Debt to Total Capital	3.67%	4.27%	4.11%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	63.25%	72.63%	84.42%	70.73%	78.47%	87.01%	103.26%	130.35%	171.02%	262.06%	533.16%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	33.08%	23.09%	11.46%	29.27%	21.53%	12.99%	-3.26%	-30.35%	-71.02%	-162.06%	-433.16%
Debt to EBITDA	-1.19	-1.21	-1.24	-2.67	-2.94	-3.68	-4.03	-1.42	-1.28	-1.19	-1.14
Net Debt to EBITDA	0.66	0.51	0.23	2.14	1.93	1.81	1.23	0.11	-0.12	-0.37	-0.57
Long-Term Debt to EBITDA	-1.13	-1.15	-1.18	-2.67	-2.94	-3.68	-4.03	-1.42	-1.28	-1.19	-1.14
Debt to NOPAT	-1.60	-1.62	-1.66	-3.55	-3.87	-4.71	-5.16	-1.94	-1.76	-1.66	-1.59
Net Debt to NOPAT	0.89	0.68	0.31	2.83	2.55	2.31	1.57	0.15	-0.16	-0.52	-0.80
Long-Term Debt to NOPAT	-1.51	-1.53	-1.58	-3.55	-3.87	-4.71	-5.16	-1.94	-1.76	-1.66	-1.59
Altman Z-Score	-3.54	-4.44	-5.57	-2.31	-3.45	-4.17	-4.98	-6.64	-7.80	-10.09	-16.05
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	8.07	5.94	7.13	8.21	6.74	6.88	5.71	4.40	3.28	2.64	2.20
Quick Ratio	7.77	5.74	6.82	7.93	6.53	6.66	5.49	4.11	3.05	2.35	1.92
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-53	-34	-32	113	39	18	29	-42	-46	-39	-36
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-152,784.62%	-88,794.34%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	-15.97	-10.49	-10.12	38.74	14.34	6.42	10.70	-15.32	-16.63	-14.01	-13.03
Operating Cash Flow to Interest Expense	-10.32	-10.32	-16.72	39.90	-11.72	-12.96	-14.47	-17.15	-13.16	-17.56	-14.05
Operating Cash Flow Less CapEx to Interest Expense	-10.32	-10.32	-16.72	39.90	-11.72	-12.96	-14.48	-17.17	-13.16	-17.56	-14.05
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.35	0.30	0.37	0.46	0.13	0.16	0.20	0.27
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.18	5.57	5.52	7.01
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	49.43	93.91	138.36	225.91	89.42	236.83	1,310.03	1,262.20
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	50.84	65.59	66.13	52.04
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	50.84	65.59	66.13	52.04
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-13	-25	-11	-76	-76	-68	-66	-61	-64	-61	-62
Invested Capital Turnover	0.00	0.00	0.00	-2.21	-2.39	-2.49	-3.21	-0.59	-0.63	-0.75	-0.87
Increase / (Decrease) in Invested Capital	25	-0.35	2.29	-65	-63	-43	-55	15	11	6.32	4.49
Enterprise Value (EV)	70	118	228	46	93	108	190	265	616	779	177
Market Capitalization	188	206	266	204	223	205	250	280	598	718	77
Book Value per Share	$0.46	$0.28	$0.12	$0.36	$0.24	$0.13	($0.03)	($0.20)	($0.36)	($0.53)	($0.69)
Tangible Book Value per Share	$0.46	$0.28	$0.12	$0.36	$0.24	$0.13	($0.03)	($0.20)	($0.36)	($0.53)	($0.69)
Total Capital	316	272	233	279	251	227	192	152	116	76	37
Total Debt	212	209	206	197	197	198	198	198	198	199	199
Total Long-Term Debt	200	197	197	197	197	198	198	198	198	199	199
Net Debt	-117	-87	-38	-157	-130	-97	-60	-15	18	62	100
Capital Expenditures (CapEx)	0.00	0.00	0.00	0.00	0.00	0.00	0.03	0.05	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-18	-30	-15	-29	-34	-30	-31	-31	-38	-33	-31
Debt-free Net Working Capital (DFNWC)	311	267	229	326	293	265	227	182	142	104	68
Net Working Capital (NWC)	299	255	219	326	293	265	227	182	142	104	68
Net Nonoperating Expense (NNE)	12	14	13	-1.45	7.06	7.74	11	11	14	15	15
Net Nonoperating Obligations (NNO)	-117	-87	-38	-157	-130	-97	-60	-15	18	62	100
Total Depreciation and Amortization (D&A)	-1.42	-2.27	-1.77	-1.68	-2.33	-2.05	-2.08	-1.49	-1.12	-0.60	-0.17
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	-30.02%	-32.14%	-25.84%	-24.63%	-76.08%	-87.06%	-67.51%	-56.15%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	339.85%	278.37%	230.93%	182.40%	453.08%	322.06%	214.99%	122.49%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	339.85%	278.37%	230.93%	182.40%	453.08%	322.06%	214.99%	122.49%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.21)	$0.00	($0.19)	$0.22	($0.14)	($0.14)	($0.16)	($0.17)	($0.21)	($0.21)	($0.20)
Adjusted Weighted Average Basic Shares Outstanding	192.88M	152.62M	225.74M	226.22M	226.35M	226.23M	226.82M	227.28M	227.98M	228.52M	234.14M
Adjusted Diluted Earnings per Share	($0.21)	$0.00	($0.19)	$0.22	($0.14)	($0.14)	($0.16)	($0.17)	($0.21)	($0.21)	($0.20)
Adjusted Weighted Average Diluted Shares Outstanding	192.88M	152.62M	225.74M	238.54M	226.35M	226.23M	226.82M	227.28M	227.98M	228.52M	234.14M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	225.41M	225.58M	226.22M	226.23M	226.60M	227.22M	227.30M	227.38M	231.46M	234.70M	234.70M
Normalized Net Operating Profit after Tax (NOPAT)	-28	-34	-29	48	-24	-25	-26	-27	-34	-32	-31
Normalized NOPAT Margin	0.00%	0.00%	0.00%	49.86%	-250.46%	-269.64%	-260.56%	-236.19%	-258.61%	-233.55%	-185.23%
Pre Tax Income Margin	0.00%	0.00%	0.00%	56.00%	-336.87%	-377.85%	-370.49%	-333.13%	-362.73%	-342.97%	-275.22%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-11.09	-13.96	-12.51	18.80	-10.84	-11.67	-12.45	-13.15	-16.80	-16.37	-16.07
NOPAT to Interest Expense	-8.48	-10.60	-9.39	16.39	-8.68	-9.24	-9.38	-9.89	-12.51	-11.71	-11.40
EBIT Less CapEx to Interest Expense	-11.09	-13.96	-12.51	18.80	-10.84	-11.67	-12.46	-13.16	-16.80	-16.37	-16.07
NOPAT Less CapEx to Interest Expense	-8.48	-10.60	-9.39	16.39	-8.68	-9.24	-9.39	-9.91	-12.51	-11.71	-11.40
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Gossamer Bio’s Q1 2026 results show a company with meaningful revenue but still deep in loss-making territory, and the balance sheet remains the key story for investors. Revenue improved year over year, but operating losses stayed large and cash burn from operations remained substantial. On the positive side, Gossamer still ended the quarter with a sizable cash and investment position, which gives it some runway. On the negative side, equity remains negative and long-term debt is still high, so dilution or further financing cannot be ruled out over time.

Q1 2026 revenue rose to $17.0 million, up from $9.9 million in Q1 2025 and $13.8 million in Q4 2025, showing continued top-line growth.
The company ended Q1 2026 with $41.0 million in cash and equivalents plus $58.2 million in short-term investments, or about $99.2 million in liquid resources.
Investing activity boosted cash during the quarter, with $41.6 million in net cash from investing activities, largely driven by sales/maturities of investments.
Deferred revenue remains meaningful at $40.6 million combined current and noncurrent, which may reflect some future revenue recognition potential.
R&D spending in Q1 2026 was $43.1 million, still the main driver of losses and consistent with a development-stage biotech profile.
SG&A expense was $18.7 million, higher than the prior quarter, suggesting operating costs remain elevated.
The company reported a net cash increase of $3.3 million in Q1 2026, but this was helped by investment sales rather than operating performance.
Operating cash flow was still sharply negative at ($38.7 million) in Q1 2026, indicating the core business continues to consume cash.
Gossamer reported a net loss of ($46.7 million) in Q1 2026, or ($0.20) per share, showing the company is still far from profitability.
Total common equity remains negative at ($161.5 million), a sign of accumulated losses and a weakened balance sheet.

Looking at the recent trend, revenue has been improving quarter by quarter from Q1 2025 through Q1 2026, but expenses have stayed much larger than sales. Operating losses have remained in the mid-$40 million range most quarters, so the main question for investors is not near-term profitability, but how long the company can fund operations without additional financing.

Balance sheet quality also worsened year over year. Total assets fell to $128.9 million in Q1 2026 from $280.6 million in Q1 2025, while total liabilities climbed to $290.4 million. That left equity deeply negative. Debt also remains significant at $198.8 million long-term, so leverage is still a concern even though the company has cash on hand.

Bottom line: Gossamer Bio is showing better revenue momentum, but it is still a cash-burning biotech with heavy losses and a strained balance sheet. Investors will likely be focused on whether upcoming clinical or commercial progress can improve revenue faster than expenses, and whether the current cash position is enough to support operations without dilution.

07/21/26 06:41 AM ETAI Generated. May Contain Errors.

Gossamer Bio Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Gossamer Bio's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Gossamer Bio's net income appears to be on an upward trend, with a most recent value of -$170.37 million in 2025, rising from -$6.77 million in 2017. The previous period was -$56.53 million in 2024. Find out what analysts predict for Gossamer Bio in the coming months.

Gossamer Bio's total operating income in 2025 was -$170.73 million, based on the following breakdown:

Total Gross Profit: $48.47 million
Total Operating Expenses: $219.20 million

Over the last 8 years, Gossamer Bio's total revenue changed from $0.00 in 2017 to $48.47 million in 2025, a change of 4,847,100,000.0%.

Gossamer Bio's total liabilities were at $295.01 million at the end of 2025, a 3.2% increase from 2024, and a 1,296.8% increase since 2018.

In the past 7 years, Gossamer Bio's cash and equivalents has ranged from $32.11 million in 2023 to $486.06 million in 2020, and is currently $37.73 million as of their latest financial filing in 2025.

Over the last 8 years, Gossamer Bio's book value per share changed from 0.00 in 2017 to -0.53 in 2025, a change of -53.0%.

Related Companies

Financial statements for NASDAQ:GOSS last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gossamer Bio (GOSS) Financials

Financials Breakdown Chart

Key Financial Trends

Gossamer Bio Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gossamer Bio (GOSS) Financials

Annual Income Statements for Gossamer Bio

Quarterly Income Statements for Gossamer Bio

Annual Cash Flow Statements for Gossamer Bio

Quarterly Cash Flow Statements for Gossamer Bio

Annual Balance Sheets for Gossamer Bio

Quarterly Balance Sheets for Gossamer Bio

Annual Metrics And Ratios for Gossamer Bio

Quarterly Metrics And Ratios for Gossamer Bio

Financials Breakdown Chart

Key Financial Trends

Gossamer Bio Financials - Frequently Asked Questions

When does Gossamer Bio's financial year end?

How has Gossamer Bio's net income changed over the last 8 years?

What is Gossamer Bio's operating income?

How has Gossamer Bio's revenue changed over the last 8 years?

How much debt does Gossamer Bio have?

How much cash does Gossamer Bio have?

How has Gossamer Bio's book value per share changed over the last 8 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools